CBMNet Member Bo Kara, to talk at ‘Focus in Frontiers in Industrial Biotechnology’, November 19th
CBMNet Member Bo Kara, Director Science and Technology at Fujifilm Diosynth Biotechnologies is to give a talk at the ‘Focus in Frontiers in Industrial Biotechnology’ event, November 19th, funded by CBMNet.
Bo leads the Science and Technology innovation activities at Fujifilm Diosynth Biotechnologies in Billingham, UK. He has over 25 years’ experience in the development, validation and commercialisation (CMC) of biologics drug substance processes for clinical manufacture using both mammalian and microbial manufacturing platforms. He has published widely and is primary inventor on a range of process/expression patents. He has developed a keen understanding of the technical, regulatory and commercial issues faced at each stage of the development of manufacturing processes for biopharmaceuticals. Prior to joining Fujifilm Diosynth Biotechnologies (previously Avecia Biologics) in August 2000, Bo Kara was Team Leader, Biotherapeutic Process Development and Technology Transfer at AstraZeneca Pharmaceuticals, UK for both microbial and cell culture derived biotherapeutics.